首页> 外文期刊>Drug Design, Development and Therapy >Design, synthesis,?and antitumor evaluation?of histone deacetylase inhibitors with?L-phenylglycine scaffold
【24h】

Design, synthesis,?and antitumor evaluation?of histone deacetylase inhibitors with?L-phenylglycine scaffold

机译:具有L-苯基甘氨酸支架的组蛋白脱乙酰基酶抑制剂的设计,合成和抗肿瘤评估

获取原文
           

摘要

Abstract: In our previous research, a novel series of histone deacetylase (HDAC) inhibitors with L-phenylglycine scaffold were designed and synthesized, among which amides D3 and D7 and ureido D18 were far superior to the positive control (suberoylanilide hydroxamic acid [SAHA]) in HDAC inhibition, but were only comparable to SAHA in antiproliferation on tumor cell lines. Herein, further structural derivation of lead compounds D3, D7, and D18 was carried out to improve their cellular activities. Most of our newly synthesized compounds exhibited more potent HDAC inhibitory activities than the positive control SAHA, and several derivatives were even better than their parent compounds. However, compared with SAHA and our lead compounds,?only secondary amine series compounds exhibited improved antiproliferative activities,?likely due to their appropriate topological polar surface area values and cell permeabilities. In a human histiocytic lymphoma (U937) xenograft model, the most potent secondary amine 9d exhibited similar in vivo antitumor activity to that of SAHA.
机译:摘要:在我们先前的研究中,设计并合成了一系列具有L-苯基甘氨酸骨架的新型组蛋白脱乙酰基酶(HDAC)抑制剂,其中酰胺D3和D7和脲基D18远远优于阳性对照(亚磺酰苯胺异羟肟酸[SAHA] )抑制HDAC,但在肿瘤细胞系的抗增殖方面仅与SAHA相当。在此,进行了前导化合物D3,D7和D18的进一步结构衍生,以改善其细胞活性。我们大多数新合成的化合物均比阳性对照SAHA表现出更强的HDAC抑制活性,并且几种衍生物甚至比其母体化合物更好。但是,与SAHA和我们的先导化合物相比,“仅仲胺系列化合物”显示出改善的抗增殖活性,这可能是由于它们具有适当的拓扑极性表面积值和细胞通透性。在人类组织细胞淋巴瘤(U937)异种移植模型中,最有效的仲胺9d表现出与SAHA相似的体内抗肿瘤活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号